Cargando…
Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis
BACKGROUND: Germline BRCA1/2 mutations are identified in 13-15% of ovarian cancers, while an additional 5-7% of ovarian cancers harbor somatic BRCA1/2 mutations. Beyond these mutations, germline or somatic aberrations in genes of the homologous recombination (HR) pathway such as RAD51B/C/D, PALB2, A...
Autores principales: | Andrikopoulou, Angeliki, Zografos, Eleni, Apostolidou, Kleoniki, Kyriazoglou, Anastasios, Papatheodoridi, Alksistis-Maria, Kaparelou, Maria, Koutsoukos, Konstantinos, Liontos, Michalis, Dimopoulos, Meletios-Athanasios, Zagouri, Flora |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754718/ https://www.ncbi.nlm.nih.gov/pubmed/36531003 http://dx.doi.org/10.3389/fonc.2022.1030786 |
Ejemplares similares
-
Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience
por: Kaparelou, Maria, et al.
Publicado: (2022) -
Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal Breast Cancer
por: Zografos, Eleni, et al.
Publicado: (2022) -
CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021) -
Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023) -
TP53 mutations determined by targeted NGS in breast cancer: a case-control study
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)